Introduction
Signal transduction initiated by the interaction of hematopoietic growth factors with their specific receptors controls survival, proliferation and at least some degree of differentiation of hematopoietic cells. [1] [2] [3] Several hematopoietic growth factors utilize members of the type III receptor tyrosine kinase (RTK) family. This family is characterized by five immunoglobulin-like folds in the extracellular domain, a single transmembrane domain and a cytoplasmic tyrosine kinase domain. 4, 5 Members of this receptor family include three receptors which play important roles in hematopoiesis, KIT, FMS and FLT3, and two receptors for PDGF. 6 In normal hematopoiesis, FLT3 is primarily expressed within the CD34
+ hematopoietic stem/progenitor cell population and a subset of the CD34 − fraction. 7 -10 FLT3 appears to play a role in the maintenance of pluripotent hematopoietic stem cells, 7, 11, 12 development of B-lymhocyte progenitors [13] [14] [15] and dendritic cells. 11, [16] [17] [18] FL binds FLT3 which induces receptor dimerization leading to activation of the tyrosine kinase domain and autophosphorylation of tyrosine residues. [19] [20] [21] Subsequent signal transduction is mediated through association and/or phosphorylation of cytoplasmic substrates including the p85 subunit of phosphatidylinositol 3Ј-kinase (PI3K), RAS/GTPase activating protein, phospholipase C␥, VAV, SHC, GRB2, CBL and proteins of the JAK-STAT pathway [22] [23] [24] [25] [26] [27] Because RTKs regulate a network of intricate signal transduction during the complex process of hematopoiesis, alterations in receptor structure and/or aberrant receptor expression have been implicated in leukemogenesis. 28, 29 Constitutive activation of tyrosine kinases through chromosomal translocations and subsequent fusions has been seen in a number of malignancies including BCR-ABL in CML, NPM-ALK in anaplastic large cell lymphoma, TEL-JAK2 in ALL and TEL-PDGFR in CMML. [30] [31] [32] [33] The translocation event in CMML results in generation of a fusion between TEL and PDGFR resulting in ligand-independent dimerization and activation of tyrosine kinase activity. 34 At present, chromosomal translocations involving FLT3 have not been detected. However, an internal tandem duplication (ITD) in the juxtamembrane region of FLT3 has been reported in 17-27% of AML, 5% of myelodysplasias (MDS) and a small number of ALL patients. AML patients with the ITD have a particularly poor prognosis. [35] [36] [37] [38] [39] [40] There is evidence that the ITD activates the tyrosine kinase activity of FLT3 leading to the constitutive phosphorylation of downstream signaling molecules including STAT5 and MAP kinase. [41] [42] [43] Receptor activation can also be mediated by coexpression of receptor and its ligand on hematopoietic cells. Coexpression of KIT/SCF and FMS/CSF-1 has been seen in a number of cases of AML. [44] [45] [46] Overexpression of FLT3 is also a common finding on leukemia cells. 21, [47] [48] [49] High levels of FLT3 were detected in most cases of B-lineage ALL and AML, as well as subsets of T-ALL and CML blast-crisis samples. Expression of FL also occurs on most leukemic cells. 9, 50 Taken together, the data on the overexpression of FLT3 and FL by the same leukemic cell suggests a possible autocrine, paracrine, or intracrine stimulatory loop which could contribute to the development or maintenance of leukemia. 51, 52 Recent studies point to the possible role an activated FLT3 could play in leukemogenesis. 27, 42 In our study, an activated FLT3 was generated by fusion of the helix-loop-helix (HLH) domain of TEL to the kinase domain of FLT3. The chimeric TEL-FLT3 was constitutively activated in the absence of FL stimulation. Constitutively activated TEL-FLT3 induced cellular transformation in transfected Ba/F3 cells and the development of leukemia in mice inoculated with the TEL-FLT3 expressing cells. Overexpression of wild-type FLT3 in Ba/F3 cells also resulted in leukemia when injected into Balb/c mice, probably through activation by endogenous ligand. A similar study using several examples of FLT3 ITDs had similar results. 42 The possible involvement of activated FLT3 in leukemia has prompted us to search for an inhibitor of FLT3 as a possible therapeutic intervention.
Selective inhibition of the kinase activity of other members of the type III RTK family has been previously reported for the low molecular weight compounds from the class of aminopyrimidines 53, 54 and tyrphostins. 55, 56 A compound from the tyrphostin class (AG1296) has been demonstrated to selectively block the kinase activities of both the PDGF receptor and KIT, but has no effect on the EGF receptor or vascular endothelial growth factor receptor, KDR. Treatment of v-sis transformed cells with AG1296 abolished the transformed phenotype in these cells. 57 Because FLT3 is a close relative of KIT and the PDGF receptors, we hypothesized that AG1296 might inhibit the activity of activated FLT3 and thus, reverse its transforming potential. In the present report, we investigated this possibility using the constitutively activated TEL-FLT3 expressed in Ba/F3 cells.
Materials and methods

Antibodies and reagents
The tyrphostins used in this study were provided by Drs Alexander Levitzki and Aviv Gazit (Hebrew University, Jerusalem, Israel). The synthetic methods and analytical data on the tyrphostins have been described previously. 55, 56 The structure of AG1296 is shown in Figure 1a . For in vitro and cellular assays, a stock solution of AG490, AG1296, AG1478 and AG1879 at a concentration of 10 mM was prepared in dimethylsulphoxide (DMSO) and stored at −20°C.
Recombinant mouse interleukin-3 (IL-3) and human FLT3 ligand (FL) were obtained from R&D Systems (Minneapolis, MN, USA). Polyclonal antibodies against FLT3 (S-18), STAT5 (which recognizes both STAT 5A and STAT 5B) and CBL were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibody against phosphotyrosine (4G10) and recombinant protein A-agarose were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). Horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (ECL) detection system were from Amersham (Arlington Heights, IL, USA).
Construction of activated FLT3 cell lines
The construction of the TEL-FLT3 chimeric protein has been described previously 27 Briefly, PCR was used to fuse the HLH domain of TEL to the cytoplasmic domain of FLT3 (Figure 1b) . The resulting TEL-FLT3 fusion product was subcloned into the expression vector pCIneo (Promega, Madison, WI, USA).
The murine IL-3 dependent pro-B cell line, Ba/F3, cultured in RPM1 1640 medium (Gibco, Grand Island, NY, USA) and supplemented with 10% fetal calf serum (FCS, Gemini Bioproduct, Inc. Calabasas, CA, USA) and 1 ng/ml recombinant murine IL-3, was electroporated (300 V/960 F) with wildtype FLT3 or TEL-FLT3 plasmid DNAs. Transfected cells were selected in 1 mg/ml G418 (GIBCO) in the presence of IL-3.
Inhibition of wild-type and constitutively activated FLT3
To screen for the ability to inhibit the kinase activity of FLT3, inhibitors were added to Ba/F3 cells expressing wild-type FLT3 or constitutively activated TEL-FLT3 at a concentration of 5 M for 4 h at 37°C. Prior to cell lysis, 100 ng/ml of FL was added to the cells expressing the wild-type FLT3 for 15 min to stimulate the FLT3 receptor. Cells from both groups were then washed twice with ice-cold phosphate buffered saline (PBS) and lysed for 30 min in ice-cold NP-40 lysis buffer (20 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 100 mmol/l NaF, 10% glycerol, 1% NP-40 and 10 mmol/l EDTA) containing protease and phosphatase inhibitors (2 mmol/l sodium orthovanadate, 50 g/ml antipain, 5 g/ml aprotinin, 1 g/ml leupeptin and 10 g/ml phenylmethylsulfonyl fluoride; Sigma, St Louis, MO, USA).
To evaluate the specificity and dose response curve of the inhibitors, a titration of each (keeping the final DMSO concentrations equal at 0.5%) was added to the TEL-FLT3 expressing cells, with or without 1 ng/ml IL-3. Clarified lysates (600 g) were incubated for 16 h at 4°C with antibodies against FLT3, STAT 5A and STAT 5B, or CBL, and then recombinant protein A-agarose was added for 3 h at 4°C. Immunocomplex was washed four times in TBST (10 mmol/l Tris-HCI, pH 7.4, 100 mmol/l NaCl, 0.1% Tween-20), twice in TBS (10 mmol/l TrisNaCl, pH 7.4, 100 mmol/l NaCl), boiled in sample buffer and resolved by SDS-polyacrylamide gel electrophoresis (PAGE). For immunoblotting, proteins were transferred to Immobilon membranes (Millipore, Bedford, MA, USA), blocked in 5% bovine serum albumin (BSA; Sigma) in TBST for 3 h and probed for 2 h at room temperature with specific primary antibodies. Blots were washed extensively in TBST and incubated with horseradish peroxidase-conjugated secondary antibody and substrate. The chemiluminescent blots were then exposed to film. In some cases, blots were stripped of antibody by washing in buffer containing 200 mmol/l glycine (pH 2.5) and 0.05% Tween-20 for 2 h at 80°C for successive probing of the same blot with different antibodies. To examine the reversibility of the inhibitory effect of AG1296, TEL-FLT3 expressing Ba/F3 cells were incubated with various concentrations of the inhibitors for 8 h followed by washing twice with medium. Thereafter, cells were plated in 96-well plates, incubated for 3 days and analyzed for uptake of MTT at daily intervals as described above.
Anti-proliferation assay
Apoptosis analysis
Fluorescein isothiocyanate (FITC)-conjugated annexin V (annexin V-FITC, (Clontech, Palo Alto, CA, USA)) binding to phospholipid phosphatidylserine was used to evaluate the induction of apoptosis by the inhibitor. Briefly, parental Ba/F3 cells and cells expressing TEL-FLT3 were collected, washed and resuspended in growth medium either with or without IL-3. Cells were then plated at 2.5 × 10 5 per well in 24-well plates in the presence or absence of various concentrations of the inhibitors. At daily intervals, cells were harvested, washed and resuspended in 200 l binding buffer. Annexin V-FITC (100 ng) and propidium iodide (500 ng) were added to the cell suspension followed by incubation at room temperature for 15 min.
Flow cytometry was performed immediately after staining on a FACSort flow cytometer (Becton Dickinson, Mountain View, CA, USA) with excitation 488 nm. Fluorescence of annexin V-FITC and DNA propidium iodide staining were measured at 515 nm and 585 nm, respectively.
Results
Inhibition of FLT3 tyrosine kinase activity in vitro by AG1296
AG1296 is a compound of the tyrphostin class (Figure 1a ) which potently inhibits both PDGF and KIT receptor actiLeukemia vation in intact cells with a high degree of specificity. 57 As an initial screening, Ba/F3 cell lines expressing wild-type FLT3 or the constitutively activated TEL-FLT3 were used to screen the inhibitors for the inhibition of FLT3 phosphorylation (which functions as a surrogate for FLT3 kinase activity). The latter cell line is convenient because TEL-FLT3 kinase activity is constitutive.
As shown in Figure 2 (upper panel), 5 M AG1296 was capable of inhibiting FLT3 phosphorylation stimulated by FL (lane 3) and phosphorylation of constitutively activated TEL-FLT3 (lane 6) in transfected Ba/F3 cells. To investigate the specificity of the inhibition, the same cell lines were also incubated with 5 M AG1478, an EGF receptor inhibitor. 58 AG1478 had no effect on phosphorylation in either case (Figure 2, lanes 4 and 7) . Roughly equivalent loading of protein was demonstrated for each protein in the presence and absence of inhibitors (Figure 2, lower panel) . Therefore, the initial study suggested that AG1296 is an inhibitor of FLT3 kinase activity working on both the FL-stimulated wild-type receptor and the constitutively activated TEL-FLT3.
Selective and dose-dependent inhibition of constitutively activated TEL-FLT3 kinase activity by AG1296
The inhibition of TEL-FLT3 phosphorylation was used to further test the specificity and to determine the IC 50 of AG1296 for activated FLT3. As shown in Figure 3 , upper panel, AG1296 potently inhibited the phosporylation of FLT3 in a concentration-dependent manner with an IC 50 of approximately 0.3 M. In contrast, there was little or no inhibition of FLT3 phosphorylation when inhibitors for JAK 2 (AG490), 59 EGF receptor (AG1478) 58 and SRC-kinase (AG1879) (personal communication) were used, even at concentrations up to 10 M. 
Anti-proliferative activity and reversal of TEL-FLT3 mediated transformation in Ba/F3 cells by AG1296
Our previous studies demonstrated that Ba/F3 cells expressing constitutively activated TEL-FLT3 acquired factor independent growth, a characteristic of cellular transformation. MTT-based cell proliferation assays were carried out to evaluate whether inhibition of TEL-FLT3 activity by AG1296 would eliminate the capability of cells to grow in the absence of IL-3. Parental Ba/F3 cells and cells expressing TEL-FLT3 were cultured for 3 days with varying concentrations of AG1296. As shown in Figure 4 , AG1296 did not significantly inhibit the proliferation of parental Ba/F3 cells, even at a concentration of 10 M (Figure  4a and f) . This eliminates the possibility that any inhibitory effect seen for AG1296 would be due to a general toxic effect on Ba/F3 cells. In contrast, AG1296 showed potent anti-proliferative activity against TEL-FLT3 expressing cells in a dosedependent manner, with an IC 50 of approximately 1.5 M at day 2 (Figure 4b and f) . The specificity of growth inhibition by AG1296 towards TEL-FLT3 expressing cells was further investigated by incubating the cells with various concentrations of the EGF receptor inhibitor, AG1478, for 3 days followed by the MTT assay. AG1478 showed only a very weak anti-proliferative activity against this cell line and only at the highest concentrations (Figure 4c and f) . This is presumably due to nonspecific toxicity of this compound towards cultured cells as it was also seen when used with parental Ba/F3 cells.
The reversibility of the anti-proliferative effects of AG1296 in culture was also investigated. Ba/F3 cells expressing TEL-FLT3 were treated with various concentrations of AG1296 for 8 h, washed free of inhibitor, and assayed daily for 3 days. As shown in Figure 4d and f, growth inhibition by AG1296 was fully reversible in TEL-FLT3 expressing cells even after incubation with 10 M AG1296 for 8 h at which point the phosphorylation of TEL-FLT3 is completely blocked (Figure 3) .
Since growth of Ba/F3 cells normally depends on IL-3 stimulation and cells transformed by TEL-FLT3 abolishes this dependence, we next examined whether or not the anti-proliferative effect of AG1296 on TEL-FLT3 expressing cells could be reversed by concurrent incubation of cells with IL-3. Addition of IL-3 to the cultures rescued the cells from growth arrest at all concentrations of AG1296 tested (Figure 4e and f) . This is strong evidence that the inhibition observed for AG1296 is specific to the FLT3 pathway and that other pathways leading to cellular proliferation are still intact.
Induction of apoptosis by AG1296 in TEL-FLT3 expressing cells
To determine whether inhibition of TEL-FLT3 activity induces apoptosis, cytofluorimetric studies based on annexin V-FITC binding and propidium iodide uptake were performed. Parental and TEL-FLT3 expressing Ba/F3 cells were exposed to various concentrations of inhibitors in the presence or absence of 1 ng/ml IL-3. Flow cytometric measurements of the percentage of cells exhibiting annexin V-FITC binding were determined at daily intervals. Parental Ba/F3 cells treated with increasing concentrations of AG1296 did not result in any increase in apoptosis even at the highest concentration of 10 M (Figure 5a ). There was a 7-15% background of apoptosis from the inhibitor-free cell cultures which reflects either nonspecific binding of annexin V-FITC and/or the normal cell turnover in the unperturbed cell cultures.
In contrast, TEL-FLT3 expressing cells demonstrated a dosedependent increase in apoptosis upon exposure to AG1296 (Figure 5b) . At 2 M, AG1296 induced apoptosis of 24% of cells by 48 h of culture. Maximum apoptotic responses of 85% and 95% were caused by 5 M and 10 M of AG1296, respectively (Figure 5b) , correlating with the decreased cellproliferation shown previously in Figure 4 . Under the same conditions, AG1478 resulted in very little induction of apoptosis even at the highest levels tested (Figure 5c ).
The addition of IL-3 to the culture medium protects the TEL-FLT3 expressing cells from apoptosis induced by AG1296, further proving that the effect of AG1296 is specific to FLT3 and leaves IL-3 mediated pathways intact (Figure 5d ).
Inhibition of TEL-FLT3 mediated STAT5 activation by AG1296
Binding of IL-3 to its cognate receptor induces tyrosine phosphorylation of proteins in the JAK-STAT signal transduction pathway. 60, 61 Among the STAT proteins, STAT 5A and STAT 5B are rapidly and prominently phosphorylated on tyrosine residues upon stimulation by IL-3. Our previous study showed that constitutively activated FLT3 also induces phosphorylation of STAT 5A and STAT 5B, similar to the levels seen by 1 and 2) , indicating that AG1296 did not interfere with IL-3-mediated phosphorylation of STAT 5A and STAT 5B. In contrast, when AG1296 was added to the culture of TEL-FLT3 expressing cells grown in the absence of IL-3, phosphorylation of both STAT 5A and STAT 5B (lane 3) was inhibited in a dose-dependent manner with an IC 50 of less than 0.5 M (lanes 4-8) . Phosphorylation of both proteins was completely restored upon addition of IL-3 to the cell cultures (lanes 9-14) . These data reinforce the finding that AG1296 inhibition is specific to FLT3 signaling. 
Inhibition of tyrosine-phosphorylation of CBL by AG1296
CBL is a 120 kDa protein originally isolated as the cellular homolog of the product of the transforming oncogene v-cbl of the Cas NS-1 retrovirus. [62] [63] [64] CBL is a target of tyrosine phosphorylation following cytokine stimulation by IL-3 and FL. 25, 65 Our previous study showed that CBL is hyper-phosphorylated in response to constitutively activated TEL-FLT3. To investigate whether AG1296 inhibits the phosphorylation of CBL, CBL was immunoprecipitated from the same lysates generated for the STAT studies. As shown in the lower panels of Figure 6 , CBL was phosphorylated in parental Ba/F3 cells with a slight reduction in the presence of 5 M AG1296 (lanes Effect of AG1296 on tyrosine-phosphorylation of STAT 5A, STAT 5B and CBL. Parental and TEL-FLT3 expressing Ba/F3 cells were grown in serum-free medium without IL-3 for 16 h followed by treatment with increasing concentrations of AG1296 for 4 h. Prior to cell lysate preparation, 1 ng/ml of IL-3 was added for 15 min to parental Ba/F3 cells and to one set of AG1296-treated TEL-FLT3 expressing Ba/F3 cells. Cell lysates were subjected to immunoprecipitation (IP) with anti-STAT 5 antibody and followed by immunoblotting (IB) consecutively with antiphosphotyrosine 4G10 antibody and anti-STAT 5 antibody (upper panels) or with anti-CBL antibody followed by immuoblotting successively with antiphosphotyrosine antibody 4G10 and anti-CBL antibody (lower panels). 
Discussion
Autoactivation of hematopoietic growth factor receptors resulting in initiation of signal transduction cascades and uncontrolled cell proliferation has been postulated as a possible mechanism for the development of leukemia. 51, 52 Data from our previous study and others have shown frequent overexpression of FLT3 in B-lineage ALL and AML, as well as in a smaller subset of T-ALL and CML blast crisis cases. 21, [47] [48] [49] High levels of expression by itself appear to lead to at least partial activation of the receptor (Tse et al, unpublished results) . In addition, expression of FL by leukemic cells is a frequent finding and FL is normally widely expressed by both bone marrow stroma and endothelial cells. 66, 67 Thus, if the receptor is being expressed by leukemic cells, it is likely to be stimulated by its ligand. FL has been shown to exert an anti-apoptotic effect on AML blasts and prevents upregulation of Bax expression, as well as stimulates a higher level of thymidine incorporation into DNA. 68 As an additional mechanism of constitutively activating the receptor, internal tandem duplications of the juxtamembrane region of FLT3 have been reported in 20% of AML patients and smaller percentages of MDS and ALL cases. [35] [36] [37] [38] Previous studies demonstrated that constitutively activated FLT3 induces factor independent cellular growth in Ba/F3 and 32D cells which resulted in leukemic development in mice Leukemia after inoculation with the transformed cells. 27, 69 Taken together, the findings of frequent overexpression of FLT3 seen in leukemias with the possibility of partial self-activation without ligand, further stimulation with ligand coexpression, and the internal tandem duplication within the FLT3 gene, make FLT3 a candidate to play an important role in leukemia. This has prompted us to search for selective FLT3 inhibitors, which might be useful for therapy of FLT3-mediated leukemias.
Tyrosine kinase inhibitors of the tyrphostin class inhibit PDGF-induced mitogenesis in bone marrow fibroblasts and rabbit vascular smooth muscle cells. 70, 71 A class of tyrphostins has been described which inhibits PDGF and KIT receptor kinase activities with both high potency and selectivity. 57 AG1296 inhibits PDGF-induced cell proliferation in Swiss 3T3 cells and reverses the transformed phenotype of sis-transfected NIH 3T3 cells. 57 The mechanism of inhibition of PDGF receptor by AG1296 has been investigated. AG1296 does not interfere with PDGF binding or with PDGF receptor dimerization, but acts by competitively inhibiting binding of ATP. 72 Since the FLT3 receptor is closely related to the PDGF and KIT receptors and the ATP-binding domains are highly conserved among the class III receptors, 5 we reasoned that AG1296 was a good candidate to inhibit the kinase activity of the activated FLT3 receptor.
AG1296 inhibited signaling from both the FL-activated wild-type receptor and the constitutively activated FLT3. AG1296 inhibited FLT3 receptor autophosphorylation with an IC 50 of approximately 0.3 M which is similar to the values measured for inhibition of the PDGF and KIT receptors. 72 This is approximately the same IC 50 that STI571 has towards BCR-ABL autophosphorylation. 73 Other kinase inhibitors of the tyrphostin class such as the JAK 2 inhibitor AG490, EGFR inhibitor AG1478 and SRC inhibitor AG1879, had little or no effect on FLT3. The inhibition of phosphorylation of STAT 5A and STAT 5B and CBL by activated FLT3 in the absence of IL-3, coupled with the rescue of this phosphorylation by IL-3 demonstrates the relative specificity of AG1296 for FLT3 (and the other members of the type III RTK family).
The data show a correlation between FLT3 inhibition and growth arrest by AG1296 in TEL-FLT3 expressing cells. The results also show that AG1296 was not a general anti-proliferative agent but exhibited selectivity for inhibition of cells expressing the constitutively activated TEL-FLT3. Parental Ba/F3 cells lacking activated FLT3 did not respond to AG1296. Moreover, the growth of TEL-FLT3 expressing cells in the presence of AG1296 could be completely rescued by the addition of exogenous IL-3. This indicates that the signal transduction cascades necessary for proliferation remain undisturbed by AG1296, further supporting the selective nature of AG1296 towards the FLT3 receptor.
Inhibition of cell growth does not necessarily translate into cell death. This may be the more important measure of inhibitor effectiveness against leukemic cells, so this aspect of AG1296 action was also investigated. In this study, we used assays combining annexin V-FITC and propidium iodide binding for detection of apoptosis after exposure of the cells to AG1296. Annexin V binding occurs early in the course of apoptosis due to loss of plasma membrane integrity resulting in the exposure of phosphatidylserine on the outer plasma membrane layer. [74] [75] [76] Apoptosis of TEL-FLT3 expressing cells correlated well with increasing concentrations of AG1296. Addition of IL-3 to inhibitor-treated cell cultures protected the cells from AG1296-induced apoptosis.
It should be noted that the IC 50 for induction of apoptosis is higher than that required for inhibition of proliferation, which is in turn higher than that required for inhibition of receptor autophosphorylation at the same time point of culture. It is possible that a partial inhibition of kinase activity slows growth, but does not lead to cell death. Thus, a more complete inhibition of kinase activity might be required to stop cell growth and an even higher degree of inhibition required to trigger apoptosis.
The exact mode of FLT3 receptor kinase inhibition by AG1296 has not been investigated but because of the highly conserved structure of the kinase domains of the type III RTKs, it is likely to reflect the mechanism of PDGF receptor kinase inhibition. 56, 72 It has been shown that AG1296 did not interfere with ligand binding to the PDGF receptor or receptor dimerization, but exhibited competitive inhibition with ATP for binding to the unstimulated or stimulated receptor.
72
AG1296 is known to inhibit the KIT and PDGF receptors and could possibly also inhibit the FMS receptor. This may increase the chance of seeing side-effects by causing alterations to cells in which these other receptors play an important role. On the other hand, STI-571 is not specific towards the ABL kinase, but also inhibits KIT and PDGFR and yet it has been used in over a thousand patients with CML with minimal side-effects. 77 Another report used the fairly nonspecific tyrosine kinase inhibitor herbimycin A to successfully inhibit FLT3 transformed 32D cells in vivo. 69 The activated FLT3 model described here may be useful for screening compounds with even higher specificity towards FLT3 to reduce the toxicity of FLT3 inhibitors in vitro and in vivo.
In summary, AG1296 represents a potent and selective inhibitor for FLT3. In the cell-based analyses, this selectivity translates into selective inhibition of FLT3 signaling without directly affecting downstream cellular molecules in the signaling cascades. As a single agent, AG1296 has an anti-proliferative potential against Ba/F3 cells transformed by activated FLT3 and results in apoptotic cell death. The biological profile of AG1296 suggests it not only acts as a tool for studying the biology of signal transduction of FLT3, but potentially is therapeutic in the treatment of leukemia cells expressing FLT3 activated by mutation or coexpression of FL. In fact, we just completed a study of primary human AML cells treated with AG1296 in vitro and saw strong cytotoxic responses of cells expressing the constitutively activated forms of FLT3 providing proof of concept for targeting AML with FLT3 inhibitors. 78 
